An API maker is worth its products, its approvals and the plant that meets the rules. We run a DCF on what each product should earn. We check it against deal multiples. Then we adjust for risk from the regulator, such as a pending inspection or an import alert.
How it usually unfolds
A mid-sized pharma firm wants a sure supply of key molecules. It plans to buy an API maker with approvals in regulated markets.
We work out sales product by product. We weigh where each approval stands. We ask how much of the sales rest on a few buyers. We read the past inspection reports and look at the state of the plant. Then we check our figure against recent pharma deals.
The buyer gets a value range. It sees the risks from the regulator that could move it. It also gets a list of points to close before it signs.
Illustrative scenario drawn from the kinds of mandates RNC handles. It does not describe a specific client.
What changes the value
| Decision point | Why it matters |
|---|---|
| Regulatory status | A pending inspection or a warning letter is a real risk. |
| Product concentration | Relying on a few molecules raises risk. |
| Capacity compliance | Capacity that meets the rules is worth more than nameplate capacity. |
What to have ready
- Revenue and margin data for each product
- Regulatory approvals and inspection history
- Plant and equipment details
- Customer contracts